Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surveillance of Complex Renal Cysts - The SOCRATIC Study (SOCRATIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04558593
Recruitment Status : Recruiting
First Posted : September 22, 2020
Last Update Posted : March 24, 2021
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Université de Sherbrooke

Brief Summary:

One third of individuals aged >60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III/IV cysts.

This is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.


Condition or disease Intervention/treatment
Complex Renal Cyst Procedure: Active surveillance Procedure: Surgery

Detailed Description:

Background: One in three patients over 60 years old will be diagnosed with a renal cyst following abdominal imaging. Traditionally, experts have recommended that complex cystic lesions (also known as Bosniak III - IV cysts) should be surgically removed, but recent evidences suggest that many are benign or have low metastatic potential. Thus, active surveillance which involves close follow-up of a patient's condition, was proposed as a tradeoff option to surgery.

Design: Multicenter observational longitudinal prospective cohort study

Objectives: The goal of this multicenter project is to conduct a prospective study with a 5-year follow-up to confirm the oncologic outcomes of active surveillance in the management of complex cysts. The main objectives are: 1) to compare the 5-year cancer specific survival between cysts managed by surgery and active surveillance; 2) to evaluate disease progression; 3) to evaluate patient's well-being according to each management strategy; and 4) to compare the 5-year healthcare cost of both management approaches.

Study population: Patients incidentally diagnosed with a Bosniak III and/or IV cysts, who are deemed to have at least 5 years of life, and who opted to be managed by either surgery or active surveillance. (N=330)

Follow-up: Patients will DECIDE if they want to have a surgery or to be followed by active surveillance. All patients will be followed as per standard of care with either semi-annual and annual visits. Research visits will serve to evaluate vital status and quality of life scores (through validated questionnaires). Patients on active surveillance will also be assessed for cyst progression and will be offered invasive or systemic therapy if progression is observed.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 330 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Surveillance of Complex Renal Cysts - The SOCRATIC Study
Actual Study Start Date : February 2, 2021
Estimated Primary Completion Date : December 20, 2029
Estimated Study Completion Date : December 20, 2030

Group/Cohort Intervention/treatment
active surveillance
220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
Procedure: Active surveillance
Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)

surgery
110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
Procedure: Surgery
Per standard of care: partial or full resection of the kidney




Primary Outcome Measures :
  1. 5-year cancer-specific survival [ Time Frame: from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years) ]
    Defined as kidney cancer survival 5 years after the enrollment


Secondary Outcome Measures :
  1. 5-year overall survival [ Time Frame: from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years) ]
    Defined as survival 5 years after enrollment

  2. 2-year overall survival [ Time Frame: from the date of enrollment (defined by signed consent) up to 2 years of follow-up ]
    Defined as survival 2 years after enrollment

  3. 2-year cancer-specific survival [ Time Frame: from the date of enrollment (defined by signed consent) up to 2 years of follow-up ]
    Defined as kidney cancer survival 2 years after the enrollment

  4. Treatment-free survival [ Time Frame: from the date of enrollment (defined by signed consent) up to 2 and 5 years of follow-up ]
    Defined as survival without treatment (in active surveillance group)

  5. Discontinuation rate [ Time Frame: from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years) ]
    Defined as the number of people who discontinued active surveillance at the end of the study (over the total)

  6. Tumor growth rate [ Time Frame: if there is a progression, at the time of imaging (undefined, between 6 months and 5 years post-enrollment) ]
    Defined by change in volume (cm3 ) and change in maximal diameter measured over time (years). Volume will be calculated using the formula for ellipsoid volume: 0.5326 x length x width x height.

  7. Tumor progression rate [ Time Frame: if there is a progression, at the time of imaging (undefined, between 3 months and 5 years post-enrollment) ]
    Defined as the percentage of patients with tumors that have met our pre-specified progression endpoints

  8. Time to tumor progression (Progression-free survival) [ Time Frame: range of time from enrollment to progression (undefined, between 3 months and 5 years post-enrollment) or end of follow-up (5 years post-enrollment) ]
    Defined as the time from the date of enrollment to the date where an individual experienced tumor progression or censoring due to lost to follow-up or the end of follow-up period

  9. Patient and tumor characteristics in correlation with cancer-specific death [ Time Frame: at the baseline visit (no more than 30 days after signed consent) ]
    Defined as demographic (i.e. age, sex, comorbidities, medical history, etc) and tumor characteristics (i.e. tumor size, tumor complexity, etc) associated with kidney cancer deaths

  10. Patient and tumor characteristics in correlation with disease progression [ Time Frame: at the baseline visit (no more than 30 days after signed consent) ]
    Defined as demographic (i.e. age, sex, comorbidities, medical history, etc) and tumor characteristics (i.e. tumor size, tumor complexity, etc) associated with disease progression.

  11. Perceived health change over time [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]
    Defined as the change in EQ5D-5L scores over time (enrollment to censoring due to lost of follow-up or the end of follow-up period).

  12. Quality of life change over time [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]
    Defined as the change in short form health survey (SF-12) scores over time (enrollment to censoring due to lost of follow-up or the end of follow-up period).

  13. Anxiety change over time [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]
    Defined as the change in Hospital Anxiety and Depression Scale (HADS) scores over time (enrollment to censoring due to lost of follow-up or the end of follow-up period).

  14. Health cost [ Time Frame: range of time from enrollment to end of follow-up (maximum 5 years post-enrollment) ]
    Defined as the total direct (patients) and indirect (healthcare system) cost associated with the management of a complex cyst according to each treatment strategy (active surveillance and surgery).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients incidentally diagnosed with a Bosniak III or IV cysts and who opted to be managed by either surgery or active surveillance
Criteria

Inclusion Criteria:

  • 18 years old and older;
  • diagnosed with a Bosniak III or IV cyst;
  • size of cystic component ≤7cm;
  • cyst wall/septum nodule <1cm for Bosniak III cysts;
  • solid component ≤2 cm in maximal diameter for Bosniak IV cysts;
  • life expectancy >5 years (by physician's estimate);
  • diagnosis ≤ 6 months from accrual date;
  • currently asymptomatic from the disease;
  • deemed fit enough for surgery;
  • willingness and ability to complete questionnaires in either French or English;
  • able and willing to provide informed consent

Exclusion Criteria:

  • history of a hereditary renal cancer syndrome;
  • presence of polycystic kidney disease;
  • any prior history of RCC;
  • received systemic therapy for another malignancy within the 12 months prior to accrual;
  • uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction/unstable angina within 6 months that would predispose to immediate surgical therapy;
  • metastatic disease or evidence of vascular or nodal disease;
  • unwillingness to undergo monitoring and imaging studies;
  • any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate <30min/mL)
  • refusing to be co-enrolled in CKCis registry (when applicable in CKCis participating centers)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04558593


Contacts
Layout table for location contacts
Contact: Amelie Tetu 819-346-1110 ext 15571 amelie.tetu.ciussse-chus@ssss.gouv.qc.ca

Locations
Layout table for location information
Canada, Ontario
St-Joseph's Hospital Not yet recruiting
Hamilton, Ontario, Canada
Contact: Camilla Tajzler         
Principal Investigator: Anil Kapoor         
The Ottawa Hospital Not yet recruiting
Ottawa, Ontario, Canada
Contact: David Yachnin         
Principal Investigator: Luke Lavallee         
Princess Margaret Hospital Not yet recruiting
Toronto, Ontario, Canada
Contact: Maria Komisarenko         
Principal Investigator: Antonio Finelli         
Canada, Quebec
CHUM Not yet recruiting
Montreal, Quebec, Canada
Contact: Amal Nadiri         
Principal Investigator: Jean-Baptiste Lattouf         
McGill University Health Centre Not yet recruiting
Montreal, Quebec, Canada
Contact: Christopher Naccache         
Principal Investigator: Simon Tanguay         
Centre de recherche du Centre hospitalier Universitaire de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Elsie Morneau    819-346-1110 ext 12827    elsie.morneau.ciussse-chus@ssss.gouv.qc.ca   
Principal Investigator: Patrick O Richard         
Canada
CHU de Québec - Université Laval Not yet recruiting
Québec, Canada
Contact: Marilyn Savard         
Principal Investigator: Frédéric Pouliot         
Sponsors and Collaborators
Université de Sherbrooke
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Patrick O Richard, MD,MSc,FRCSC Université de Sherbrooke
Layout table for additonal information
Responsible Party: Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT04558593    
Other Study ID Numbers: 2020-3522
First Posted: September 22, 2020    Key Record Dates
Last Update Posted: March 24, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Université de Sherbrooke:
renal cyst
complex cyst
Bosniak III
Bosniak IV
renal masses
active surveillance
monitoring
surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Cysts
Kidney Diseases, Cystic
Neoplasms
Pathological Conditions, Anatomical
Kidney Diseases
Urologic Diseases